You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森制药(03692.HK)年度纯利达25.69亿元 末期息6.51分
格隆汇 03-30 16:57

格隆汇3月30日丨翰森制药(03692.HK)公布,截至2020年12月31日止年度,公司收入86.9亿元人民币,同比增长0.1%;期间溢利25.69亿元,同比增长0.5%;每股盈利0.44元,末期股息每股人民币6.51分。

公司是中国制药公司当中研发团队规模最大的公司之一。公司的专责专业研发团队由位于上海、连云港和常州的三个开发中心的超过1,600名研究人员组成。公司拥有多个国家级研发称号,包括国家级技术中心、博士后科研工作站及国家重点实验室。

期间研发开支约人民币12.5亿元,同比增长约11.7%,占收入比例约14.4%。新产品销售占集团收入约23.7%;2019年度,新产品销售占集团收入约6.1%。

2020年,尽管突如其来的新冠疫情影响了社会经济发展,但中国有效的管控措施,使得社会经济活动恢复正常,进入到疫情常态化的状态。因疫情的影响,广大民众对于健康的意识反而进一步提高,中国巨大的医疗需求不断提升。国家医改持续深入推进,医疗保障制度、药品管理制度和药品一致性评价等方面新政策实施落地,为整个医药行业的发展带来重大挑战与机遇。

面对政策环境、市场环境的新变化以及疫情的影响,公司积极应对,坚定并加快创新发展的步伐,实现全面转型升级。随着阿美乐(甲磺酸阿美替尼片)、孚来美(聚乙二醇洛塞那肽注射液)、豪森昕福(甲磺酸氟马替尼片)三个1类创新药的获批并纳入医保,公司的创新转型已步入收获期,公司的综合竞争力进一步得到提升。公司相信,随着不断增强的创新能力,进一步丰富产品管线组合,维持高层次产品质量,保障稳定的生产供应,依托自身积累的出色的商业化能力,将推动公司持续、稳定、健康发展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account